As demand for CAR T therapies strain traditional manufacturing, Autolus Therapeutics has tapped Cellares to evaluate whether that company’s automated Cell Shuttle platform can support expanded ...

Researchers hope to undertake clinical studies in multiple cancers, including ovarian cancer, glioblastoma, and others.

Gilead is now waiting upon the FDA’s approval of anito-cel, Arcellx’s lead candidate, slated for December 2026.

A method called "in vivo CAR-T (in vivo CAR-T·in vivo CAR-T)" that directly alters immune cells within the body with a single injection is recently transforming the cancer treatment market. This ...

What major challenge of traditional CAR-T does the in vivo alleviate/address? In addi | Dr Adrian Bot, Capstan Therapeutics, ...

RNA CAR T therapy Descartes‑08 targets BCMA‑positive plasma cells and delivers year‑long symptom relief in myasthenia gravis after a brief course, signaling a new era of durable treatment.

Researchers at the Keck School of Medicine of University of Southern California (USC) have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response ...

BEIJING, Dec. 21, 2025 /PRNewswire/ -- T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food and Drug ...

The last time I wrote about Allogene Therapeutics, Inc. (ALLO) it was in a Seeking Alpha article entitled "Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products." I noted the ...

Could CAR-T, the immunotherapy that has transformed treatment for some cancers, hold promise for Alzheimer’s? In the February 9 PNAS, scientists led by Jonathan Kipnis at Washington University in St.